Unlike plant-based systems that suffer from low protein expression and high scaling costs, silkworm pupae function as dense, natural bioreactors. This allows for high-yield production at a low cost, making oral vaccines commercially viable where previous attempts have failed.

To ensure pharmaceutical-grade consistency from a living organism, Kaiko addresses biological variability with stringent controls. This includes using Specific Pathogen-Free (SPF) grade pupae from specialized facilities and collaborating directly with regulatory bodies like Japan's PMDA to establish clear acceptance criteria, aligning the novel platform with pharmaceutical expectations.

The silkworm platform changes the manufacturing paradigm from "scaling up" to "scaling out." Instead of building larger, more expensive bioreactors, production is increased simply by using more pupae. This model offers greater flexibility to adapt to demand, lowers infrastructure costs, and reduces the engineering risks associated with traditional scale-up.

Contrary to the belief of those outside manufacturing, establishing a bioprocess is not a one-time task. The inherent unpredictability of biology means things will inevitably go wrong even in the most controlled environments, making it a continuous and difficult challenge.

Unlike a drug that can be synthesized to a chemical standard, most vaccines are living biological products. This means the entire manufacturing process must be perfectly managed and cannot be altered without re-validation. This biological complexity makes production far more difficult and expensive than typical pharmaceuticals.

Contrary to the belief that living organisms are too variable for biomanufacturing, Kaiko's work shows that silkworms can be powerful and consistent bioreactors. With the right controls, this platform produces pharmaceutical-grade proteins, including vaccine antigens, meeting modern regulatory expectations and creating new manufacturing possibilities.

Silkworm biomanufacturing offers incredible production density, with one pupa producing 10-20 mg of protein. Scaling requires simply adding more pupae ('scaling out') rather than building larger facilities ('scaling up'), enabling decentralized, small-footprint manufacturing.

Unlike autologous therapies where one batch treats one patient, a single batch of an allogeneic therapy can treat thousands. This scalability advantage creates a higher regulatory bar. Authorities demand exceptional robustness in the manufacturing process to ensure consistency and safety across a vast patient population, making the quality control challenge fundamentally different and more rigorous.

Unlike traditional biologics with consistent inputs, cell therapy success is dictated by the highly variable quality of patient cells. Heavily pretreated patients yield cells that behave unpredictably, meaning a standard process will inevitably produce a variable product. This fundamental challenge is often underestimated in process development.